Identification of CRYAB

BMP NOTCH1 pathway brain tumors cellular heterogeneity diffuse IDH1-mutant gliomas diffuse grade II IDH-mutant glioma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 Apr 2021
Historique:
received: 03 02 2021
revised: 18 04 2021
accepted: 21 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

Diffuse grade II IDH-mutant gliomas are slow-growing brain tumors that progress into high-grade gliomas. They present intratumoral cell heterogeneity, and no reliable markers are available to distinguish the different cell subtypes. The molecular mechanisms underlying the formation of this cell diversity is also ill-defined. Here, we report that SOX9 and OLIG1 transcription factors, which specifically label astrocytes and oligodendrocytes in the normal brain, revealed the presence of two largely nonoverlapping tumoral populations in IDH1-mutant oligodendrogliomas and astrocytomas. Astrocyte-like SOX9

Identifiants

pubmed: 33925547
pii: cancers13092107
doi: 10.3390/cancers13092107
pmc: PMC8123787
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Oncotarget. 2014 Jun 15;5(11):3636-50
pubmed: 25004243
BMC Clin Pathol. 2005 Jul 15;5:6
pubmed: 16018821
Stem Cells. 2007 Feb;25(2):340-53
pubmed: 17053213
Stem Cells. 2013 Apr;31(4):741-51
pubmed: 23307615
Acta Neuropathol. 2017 Jun;133(6):1001-1016
pubmed: 28255664
Differentiation. 2001 Dec;69(2-3):135-44
pubmed: 11798067
Neuron. 1996 Oct;17(4):595-606
pubmed: 8893018
Ann Neurol. 2003 Apr;53(4):524-8
pubmed: 12666121
Acta Neuropathol. 1984;64(4):265-72
pubmed: 6391068
CNS Oncol. 2015;4(5):287-94
pubmed: 26545048
Glia. 2020 Oct;68(10):1957-1967
pubmed: 32086854
Brain Res Dev Brain Res. 1989 Mar 1;46(1):115-22
pubmed: 2706765
Glia. 2018 Feb;66(2):239-255
pubmed: 29027701
Exp Eye Res. 2009 Oct;89(4):549-58
pubmed: 19490914
Cancer Res. 2004 Oct 1;64(19):6892-9
pubmed: 15466178
Nat Med. 2008 Mar;14(3):299-305
pubmed: 18297084
Development. 2012 Jul;139(14):2488-99
pubmed: 22675211
Bioessays. 2005 Feb;27(2):115-8
pubmed: 15666349
Science. 2017 Mar 31;355(6332):
pubmed: 28360267
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2577-84
pubmed: 24072698
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
Anticancer Res. 1981;1(4):243-8
pubmed: 7345968
Genome Res. 2014 Nov;24(11):1765-73
pubmed: 25135958
Mol Cancer Res. 2014 Feb;12(2):283-94
pubmed: 24269952
Cells. 2020 Oct 15;9(10):
pubmed: 33076453
Neurochirurgie. 2017 Jun;63(3):243-249
pubmed: 28185647
Cell Death Dis. 2020 Nov 21;11(11):998
pubmed: 33221817
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6
pubmed: 22323597
Nature. 2016 Nov 10;539(7628):309-313
pubmed: 27806376
Brain Pathol. 2013 Jan;23(1):13-8
pubmed: 22672415
Nat Rev Cancer. 2015 May;15(5):302-10
pubmed: 25855404
J Neuropathol Exp Neurol. 2013 Jan;72(1):61-6
pubmed: 23242283
Oncogene. 2003 Oct 2;22(43):6661-8
pubmed: 14555979
Neuron. 1998 Jul;21(1):63-75
pubmed: 9697852
Folia Neuropathol. 2001;39(1):19-26
pubmed: 11678347
Br J Cancer. 2020 May;122(11):1580-1589
pubmed: 32291392
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Onco Targets Ther. 2019 May 30;12:4129-4139
pubmed: 31239701
J Neurooncol. 2014 Mar;117(1):53-65
pubmed: 24473683
Virchows Arch. 2015 Apr;466(4):433-44
pubmed: 25861023
J Neurooncol. 2011 Jul;103(3):417-27
pubmed: 21063898
J Neuropathol Exp Neurol. 2003 Dec;62(12):1265-75
pubmed: 14692702
J Neuropathol Exp Neurol. 2004 May;63(5):499-509
pubmed: 15198128
Glia. 2006 Aug 15;54(3):223-33
pubmed: 16817201
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13
pubmed: 1584765
Cancer Res. 2007 Dec 1;67(23):11244-53
pubmed: 18056450
Stem Cells. 2015 Jan;33(1):21-34
pubmed: 24898819
Nature. 2007 Jul 26;448(7152):474-9
pubmed: 17568699
Acta Neuropathol. 1996;91(1):99-103
pubmed: 8773153
Sci Signal. 2009 Sep 08;2(87):re6
pubmed: 19738203
J Biol Chem. 2004 Aug 6;279(32):33946-57
pubmed: 15173171
Cancer Res. 2011 Jun 1;71(11):3812-21
pubmed: 21512138
Sci Rep. 2020 Mar 26;10(1):5504
pubmed: 32218467
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56
pubmed: 17146289
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Annu Rev Physiol. 2012;74:245-69
pubmed: 21942705
Oncotarget. 2012 Jul;3(7):709-22
pubmed: 22869205
J Neurooncol. 2012 May;108(1):69-75
pubmed: 22392125
Annu Rev Neurosci. 2002;25:471-90
pubmed: 12052917
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Nature. 2012 Feb 15;483(7390):474-8
pubmed: 22343901
Am J Pathol. 1989 Sep;135(3):529-40
pubmed: 2675625

Auteurs

Meera Augustus (M)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.

Donovan Pineau (D)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.

Franck Aimond (F)

Institut des Neurosciences de Montpellier (INM), University of Montpellier, CEDEX 5, 34091 Montpellier, France.

Safa Azar (S)

Institut des Neurosciences de Montpellier (INM), University of Montpellier, CEDEX 5, 34091 Montpellier, France.

Davide Lecca (D)

Department of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.

Frédérique Scamps (F)

Institut des Neurosciences de Montpellier (INM), University of Montpellier, CEDEX 5, 34091 Montpellier, France.

Sophie Muxel (S)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.

Amélie Darlix (A)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.
Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier, 34000 Montpellier, France.

William Ritchie (W)

Institut de Génétique Humaine (IGH), University of Montpellier, CNRS, 34396 Montpellier, France.

Catherine Gozé (C)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.
Laboratory of Solid Tumors Biology, Hôpital Lapeyronie, 371 Avenue du Doyen Giraud, 34295 Montpellier, France.

Valérie Rigau (V)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.
Department of Pathology and Oncobiology, Hôpital Gui de Chauliac, 80 Avenue Augustin Fliche, 34295 Montpellier, France.

Hugues Duffau (H)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.
Neurosurgery Department, Hôpital Gui de Chauliac, 80 Avenue Augustin Fliche, 34295 Montpellier, France.

Jean-Philippe Hugnot (JP)

Institut de Génomique Fonctionnelle (IGF), University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.
Department of Biology, University of Montpellier, Place Eugène Bataillon, CEDEX 05, 34095 Montpellier, France.

Classifications MeSH